Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed
- PMID: 5789809
- PMCID: PMC1703604
- DOI: 10.1111/j.1476-5381.1969.tb08011.x
Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed
Abstract
1. Six ergot alkaloids were tested for their effect on vascular resistance and for alpha-adrenergic blocking activity on the innervated perfused hind limb of the dog. The results were compared with those obtained earlier for three compounds of the ergotamine group.2. Ergostine, dihydroergostine, 1-methylergostine and dihydroergocristine resembled ergotamine, dihydroergotamine and 1-methylergotamine in eliciting vasoconstriction at low vascular resistance and vasodilatation at high vascular resistance. The changeover occurred at the following "inversion points": ergostine and dihydroergostine as with ergotamine and dihydroergotamine at about 4 R.U.; 1-methylergostine as with 1-methylergotamine at about 2.3 R.U.; dihydroergocristine at about 1.9 R.U. [1 R.U. = 1 resistance unit = 1 mm Hg/ml. per min.]3. 1-methyldihydroergocristine consistently elicited vasodilatation (for initial vascular resistances down to 1.3 R.U.) and 5'-methylergoalanine always caused vasoconstriction (for initial values up to 5.8 R.U.).4. Ergostine and 5'-methylergoalanine had the most powerful vasoconstrictor effect, which was of the same order of magnitude as that of ergotamine. Dihydroergostine, like dihydroergotamine, was considerably less active. Both 1-methylergostine and 1-methylergotamine elicited only weak vasoconstriction. Moreover, when the initial vascular resistance exceeded the critical inversion value, they elicited only weak vasodilatation. Dihydroergocristine and 1-methyldihydroergocristine had the least effect on vascular resistance.5. The increase in vascular resistance by noradrenaline was inhibited in a dose-dependent manner by all the ergot alkaloids investigated. Ergostine, 5'-methylergoalanine and ergotamine had the greatest alpha-adrenergic blocking activity and 1-methylergostine, 1-methyldihydroergocristine and 1-methylergotamine the weakest. The activity of dihydroergostine, dihydroergocristine and dihydroergotamine fell between these two extremes.6. No correlation was found between the qualitative effect of these ergot alkaloids on vascular resistance (inversion point) and (a) their quantitative effect on this parameter or (b) their alpha-adrenergic blocking activity. Determination of the inversion point thus provides additional pharmacological information on the vasoactive properties of the ergot alkaloids.
Similar articles
-
[Peripheral circulatory effects of ergotamine, dihyroergotamine and 1-methylergotamine on the innevated, perfused hindlimb of the o].Helv Physiol Pharmacol Acta. 1967;25(4):374-96. Helv Physiol Pharmacol Acta. 1967. PMID: 5585259 German. No abstract available.
-
[Effect of ergot alkaloids on venous tonus determined in superficial hand veins in situ].Cardiology. 1976;61 suppl 1:302-8. doi: 10.1159/000169823. Cardiology. 1976. PMID: 975144 German.
-
Pharmacological basis of the treatment of orthostatic disorders with ergot alkaloids.Cardiology. 1976;61 suppl 1:290-301. doi: 10.1159/000169822. Cardiology. 1976. PMID: 975143
-
Pharmacology of ergot alkaloids in clinical use.Med J Aust. 1978 Nov 4;2(3 Suppl):3-13. doi: 10.5694/j.1326-5377.1978.tb77379.x. Med J Aust. 1978. PMID: 370528 Review. No abstract available.
-
The pharmacology of ergotamine and dihydroergotamine.Headache. 1997;37 Suppl 1:S15-25. Headache. 1997. PMID: 9009470 Review.
Cited by
-
Effect of dihydroergocristine infusion on tolbutamide-induced insulin secretion in man.Experientia. 1979 Oct 15;35(10):1402-4. doi: 10.1007/BF01964035. Experientia. 1979. PMID: 115708
-
Clinical pharmacokinetics of ergotamine in migraine and cluster headache.Clin Pharmacokinet. 1985 Jul-Aug;10(4):334-52. doi: 10.2165/00003088-198510040-00004. Clin Pharmacokinet. 1985. PMID: 3899452 Review.
-
Actions of co-dergocrine mesylate and its components at vascular smooth muscle.Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. doi: 10.1007/BF00500484. Naunyn Schmiedebergs Arch Pharmacol. 1982. PMID: 7063048
-
Effects of dihydroergotamine (DHE) on blood flow and metabolism in the underperfused myocardium in anaesthetized dogs.Basic Res Cardiol. 1984 Jul-Aug;79(4):461-8. doi: 10.1007/BF01908147. Basic Res Cardiol. 1984. PMID: 6487239
-
Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.Eur J Clin Pharmacol. 1991;41(6):597-602. doi: 10.1007/BF00314992. Eur J Clin Pharmacol. 1991. PMID: 1815973 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources